Gain Therapeutics (NASDAQ:GANX) Upgraded at Roth Capital

Roth Capital upgraded shares of Gain Therapeutics (NASDAQ:GANX) to a strong-buy rating in a research report sent to investors on Thursday,Zacks.com reports.

Other research analysts have also issued reports about the company. Oppenheimer reaffirmed an “outperform” rating and set a $8.00 target price on shares of Gain Therapeutics in a research report on Wednesday, August 14th. Roth Mkm began coverage on Gain Therapeutics in a research report on Friday. They set a “buy” rating and a $7.00 target price for the company. HC Wainwright reissued a “buy” rating and issued a $8.00 price objective on shares of Gain Therapeutics in a research note on Monday, November 25th. Finally, Chardan Capital reissued a “buy” rating and issued a $6.00 price objective on shares of Gain Therapeutics in a research note on Friday, August 9th. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $7.25.

Gain Therapeutics Trading Up 4.7 %

GANX stock opened at $1.79 on Thursday. The company has a market cap of $47.47 million, a P/E ratio of -1.63 and a beta of 0.21. The company has a quick ratio of 2.99, a current ratio of 2.99 and a debt-to-equity ratio of 0.04. Gain Therapeutics has a twelve month low of $0.89 and a twelve month high of $5.33. The business has a fifty day moving average of $2.09 and a 200-day moving average of $1.68.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Hohimer Wealth Management LLC acquired a new position in shares of Gain Therapeutics in the 2nd quarter valued at about $422,000. Geode Capital Management LLC increased its position in Gain Therapeutics by 48.0% in the 3rd quarter. Geode Capital Management LLC now owns 271,972 shares of the company’s stock valued at $484,000 after buying an additional 88,236 shares in the last quarter. Renaissance Technologies LLC increased its position in Gain Therapeutics by 154.2% in the 2nd quarter. Renaissance Technologies LLC now owns 118,700 shares of the company’s stock valued at $152,000 after buying an additional 72,000 shares in the last quarter. Finally, Warberg Asset Management LLC bought a new stake in Gain Therapeutics in the 2nd quarter valued at about $66,000. 11.97% of the stock is owned by institutional investors and hedge funds.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.